RxDoctor Payments Data

Hripsime Manukyan

Acute Care · Glendale, CANPI 1841956760

Payments from drug & device makers

$2,461in general payments, 2019–2025

Across 116 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$779
  • Regeneron Healthcare Solutions, Inc.$415
  • Baxter Healthcare$325
  • Pharming Healthcare, Inc.$161
  • AstraZeneca$129
  • Boehringer Ingelheim$106
  • plus $545 from 13 others

What the payments were for

  • Food & beverage$2,41698%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,461 in reported general payments places this provider in the 85th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$59,906
Medicare patients
379
Services billed
638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter313$242,774
OfevNintedanib Esylate15$191,190
Breo ElliptaFluticasone/Vilanterol116$56,757
Zileuton ErZileuton16$47,499
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$34,937
Spiriva RespimatTiotropium Bromide15$17,101
EliquisApixaban19$16,225
Albuterol Sulfate HfaAlbuterol Sulfate183$7,112
Combivent RespimatIpratropium/Albuterol Sulfate11$5,162
Ventolin HfaAlbuterol Sulfate70$4,185
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$3,577
Sildenafil Citrate11$2,017
Azelastine Hcl24$859
Fluticasone Propionate68$523
Methylprednisolone52$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$779$299,531429 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$106$213,45241 claims
AstraZenecaBreztri Aerosphere$129$34,93745 claims
PfizerEliquis$32$16,22519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,153 acute care providers in California.

Other acute care in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →